JonesResearch analyst Justin Walsh initiated coverage of RenovoRx with a Buy rating and $8 price target. RenovoRx is a commercial stage medical technology company with an FDA-cleared dual-balloon catheter, RenovoCath, designed to improve delivery of anti-cancer drugs to tumors with poor blood supply, the analyst tells investors in a research note. The firm sees the device being "particularly useful" for treating pancreatic cancer.
